PlainRecalls
FDA Drug Low Class III Terminated

mitoXANTRONE Injection USP (concentrate), 20 mg/10 mL (2 mg/mL), 10 mL Multiple Dose Vial packaged in a carton, Rx only, Teva Parenteral Medicines, Inc., Irvine, CA 92618, NDC 0703-4685-01.

Reported: August 3, 2016 Initiated: May 31, 2016 #D-1451-2016

Product Description

mitoXANTRONE Injection USP (concentrate), 20 mg/10 mL (2 mg/mL), 10 mL Multiple Dose Vial packaged in a carton, Rx only, Teva Parenteral Medicines, Inc., Irvine, CA 92618, NDC 0703-4685-01.

Reason for Recall

Failed Impurities/Degradation Specifications: High out of specification results for Impurity D.

Details

Recalling Firm
Teva North America
Units Affected
2,506 vials
Distribution
Nationwide
Location
Horsham, PA

Frequently Asked Questions

What product was recalled?
mitoXANTRONE Injection USP (concentrate), 20 mg/10 mL (2 mg/mL), 10 mL Multiple Dose Vial packaged in a carton, Rx only, Teva Parenteral Medicines, Inc., Irvine, CA 92618, NDC 0703-4685-01.. Recalled by Teva North America. Units affected: 2,506 vials.
Why was this product recalled?
Failed Impurities/Degradation Specifications: High out of specification results for Impurity D.
Which agency issued this recall?
This recall was issued by the FDA Drug on August 3, 2016. Severity: Low. Recall number: D-1451-2016.